It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

Ayrmid has offered to buy bluebird for an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable upon achievement of a net sales milestone, said ...

Bluebird bio on Friday confirmed it has received an unsolicited take-over offer from the Ireland-based investment firm Ayrmid ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s ...

Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from Ayrmid Ltd.

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and SK Capital.

(BLUE) confirmed it has received an unsolicited non-binding written proposal from Ayrmid Ltd to acquire bluebird for an upfront ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal ...

March 28, 2025--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ...